## **B2.** Eligibility Criteria for Key Questions 1-5

## INCLUSION / EXCLUSION FORM

Reviewer: Ref ID:				
	CRITERIA	Yes	No	Unclear
1. PUBLICATION TYPE				
a)	Report of primary research			
b)	Full report available (Exclude abstracts and conference proceedings)			
c)	English language			
/	Published in 1995 onward			
<u>d)</u>		. Ц		
2. STUI	DY DESIGN			
a)	Comparative study design (2 or more groups); one of:			
	i. RCT			
	ii. NRCT			
	iii. Prospective or retrospective cohort studies (with concurrent or			
	nonconcurrent/historical control groups)			<u>.</u>
3. POPULATION				
a)	Pregnant women (any duration of gestation); Exclude if >20% of enrolled			
	women had known pre-existing diabetes <b>and</b> no subgroup analysis			
4. INTERVENTION				
a)	Evaluating any GDM screening or diagnostic approach, (KQ1 & 2) or			
	screening / diagnostic threshold (KQ3) and/or			
b)	Evaluating <b>any</b> treatment for GDM (KQ4 & 5)			
5. COMPARATORS				
One or 1	more of the following:			
a)	Any reference standard, other screening / diagnostic test, or criteria (KQ1)			_
,	[note: can also be a risk-factor if used for screening];			
b)	No screening / diagnostic test for GDM (KQ2);			
c)	Patients meeting different screening / diagnostic threshold for GDM (e.g.,			
	GDM vs. no GDM) (KQ3);			
d)	Placebo or no treatment (KQ4 & 5)			
	Exclude studies that compare 2 or more treatment, but have no placebo,			
	standard care or no treatment group			
6. OUTCOME				
	e or more of the following:			
a)	Test properties (i.e., sensitivity, specificity, predictive values, accuracy; <i>not</i>			
••)	yield only);			
b)	Maternal outcomes:			
,	i. Short-term: preeclampsia/maternal hypertension, cesarean delivery,			
	depression, birth trauma, mortality, weight gain, other morbidity			
	ii. Long-term: Type 2 DM risk, obesity, hypertension			
c)	Fetal/neonatal/child outcomes:			
	i. Short-term: macrosomia, shoulder dystocia, clavicular fracture,			
	brachial plexus injury, birth injury, hypoglycemia, hyperbilirubinemia,			
	mortality, other morbidity			
	ii. Long-term: obesity, type 2 DM, transgenerational GDM			
d)	Any adverse events or harms of screening or treatment (e.g., anxiety, healthcare			
	system issues, burden on practitioner's office, increased interventions,			
	postpartum depression, small for gestational age, costs, resource allocations)			
Comments:				
REVIEWER'S DECISION: Include ☐ Exclude ☐ Unsure ☐				
RELEVANT TO QUESTION(S): KQ1 $\square$ KQ2 $\square$ KQ3 $\square$ KQ4 $\square$ KQ5 $\square$				